Category: Equities
-
Buffett Steps Down as Berkshire Chairman: The Six-Decade Era Ends, the Abel Era Accelerates
Warren Buffett, 96, stepped down as Berkshire Hathaway chairman, handing the board to his son Howard while Greg Abel runs the company. Inside the two-step succession, the $365 billion war chest, and the capital allocation regime change already under way.
-
The AI Safety Selloff: The Week the Builders Asked to Slow Down
Anthropic’s Dario Amodei called for slowing frontier AI development, Altman and Musk agreed, and the Philadelphia Semiconductor Index fell 5.9 per cent in a day. Inside the AI safety selloff: the doomsday trade’s strange shape, the OpenAI cash question and the new pacing risk premium.
-
Lululemon Q2 Earnings: The $134.5 Million Refund Behind a 15 Per Cent Fall
Lululemon Q2 earnings beat on a one-off tariff refund while revenue fell 4.3 per cent and guidance was cut by double digits, sending shares below $100.
-
Broadcom AI Revenue Tripled to $16.7 Billion. The Stock Fell Anyway.
Broadcom grew AI semiconductor revenue 221 per cent to $16.7 billion, printed a record $29.6 billion quarter and $13.7 billion of free cash flow, then fell around 5 per cent on a guidance figure seven tenths of one per cent light. Inside the grading curve the market now applies to the AI trade.
-
Shein’s Hong Kong IPO: A $100 Billion Story Lists at $26.5 Billion
Shein priced its Hong Kong IPO at $26.5 billion, 73 per cent below its 2022 private valuation, and fell 9 per cent on debut. Inside the growth collapse, the de minimis shock and what the listing says about the new tariff economy.
-
Nvidia Q2 Earnings: The $96 Billion Quarter the Market Finally Bought
Nvidia grew revenue 106 per cent to $96.2 billion, guided $4 billion above consensus and tripled its AWS order book, then told investors margins are heading down before they head up. Inside the first Nvidia print in a year the market chose to buy.
-
Retail Earnings Week: Tariff Refunds, a Walmart Warning and a Narrowing Consumer
Walmart’s slowest US comps in six years, Target’s traffic beat, a frozen housing market, and billions in tariff refunds flattering the sector’s profits. Inside a distorted retail earnings week and what it really says about the US consumer.
-
The mRNA Cancer Vaccine Breakthrough: $92 Billion Repriced on a Result Nobody Has Seen
Moderna and Merck’s personalised mRNA cancer vaccine met its goals in the Phase 3 INTerpath-001 melanoma trial, the first late-stage success for the technology. Roughly $92 billion of market value moved on an announcement that contained no efficacy figure at all.
-
The Small-Cap Rotation Week: Russell 2000 Records While the Market Sells AI Beats
The Russell 2000 closed the week at a record 3,068, its 27th of 2026, while record results from Applied Materials and a $4 billion guidance beat from Cisco were both sold. Inside the small-cap rotation, the AI trade’s new grading curve, and what decides whether the broadening lasts.
-
CoreWeave Q2 2026 Earnings: The $104 Billion Backlog and the $640 Million Interest Bill
CoreWeave doubled revenue to $2.58 billion and grew its backlog 246 per cent to $104 billion. It also paid $640 million in interest, which is what turned a profitable operation into a $626 million loss. Inside the quarter that priced the debt-funded AI model.